The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.
about
Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitorsDynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.Emerging drugs for myelofibrosis.Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCTAllogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party oRole of hematopoietic stem cell transplantation in patients with myeloproliferative disease.How to manage the transplant question in myelofibrosis.Effects of spleen status on early outcomes after hematopoietic cell transplantation.Experimental therapeutics for patients with myeloproliferative neoplasias.Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.New JAK2 inhibitors for myeloproliferative neoplasms.Allogeneic stem cell transplantation for myelofibrosis in 2012.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.Current Challenges in Stem Cell Transplantation in Myelofibrosis.Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis.Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis.Guideline for the diagnosis and management of myelofibrosis.Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.How to manage polycythemia vera.Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
P2860
Q26863610-682C74DC-C423-45D3-8BA5-35291BD6AF56Q33400683-D84F66CF-AB28-41B9-95EE-C93408520A2CQ33404574-25B7EBA5-9A07-4017-991E-0733432913EBQ33556843-B1517619-A8D9-4B15-9E81-24EB87D9FF7FQ33558748-352F1322-A801-4D29-8A8A-7A2BAEC832CFQ34625390-2B95D6C6-47E8-4501-84BD-3202EDD4F2A3Q35865676-D7C9C71B-3C1B-46D6-9F50-CFDA075B5682Q36712192-6AD2E9F7-37A5-44E3-A861-AE7ACEE748B2Q37797983-84BC4646-420E-4E4A-B833-5F9487009AA5Q37833893-5255580F-450B-4511-AA32-451D476AD25FQ37869152-A4BE59FB-E695-46C9-A3A6-560797DED64AQ37998567-B3D6E047-F2C8-4921-A652-8D6C60DD69E0Q38018908-14F6850E-3C8A-410B-929B-110F4E070D74Q38081267-7B1FDE97-3B2F-456F-9B53-F333F0586F72Q38174781-B9BBB009-E806-41D7-A1A6-FE7E0D5B7853Q38236642-E21941AC-E800-4C76-9822-08C2A9534216Q38569146-911A2D94-FF21-40DA-AEC0-1FE850C11A3DQ38570614-3C2C10B2-3DB7-4849-B23D-27CCC1C98E2AQ39157279-DBC8425D-2C9B-4B3F-86E3-F4FBD3B96916Q40453557-1FF342EC-29AC-4C63-9924-65C3A2692051Q41519713-81558C8C-F23E-4217-A848-23671A232C0FQ45060240-D6B6D7EF-45E7-4FCB-B118-A41C40F4F06EQ50495964-23BE97B1-C163-48A4-968B-A5B0A116EF1FQ53099028-B6CE82F5-960E-46D6-97EF-A0EA2BCAEE48Q54544165-21763C8D-3DEA-450B-937D-21CBC9425D25Q54573577-5587C6A9-36E9-46B2-A04D-962C319507CF
P2860
The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The role of allogeneic SCT in ...... Marrow Transplantation study.
@en
The role of allogeneic SCT in ...... Marrow Transplantation study.
@nl
type
label
The role of allogeneic SCT in ...... Marrow Transplantation study.
@en
The role of allogeneic SCT in ...... Marrow Transplantation study.
@nl
prefLabel
The role of allogeneic SCT in ...... Marrow Transplantation study.
@en
The role of allogeneic SCT in ...... Marrow Transplantation study.
@nl
P2093
P2860
P356
P1476
The role of allogeneic SCT in ...... d Marrow Transplantation study
@en
P2093
British Society for Blood and Marrow Transplantation
G McQuaker
J Apperley
K E Kirkland
P D Kottaridis
P2860
P2888
P304
P356
10.1038/BMT.2010.14
P407
P577
2010-02-15T00:00:00Z
P5875
P6179
1009258274